S-1/A: GRI Bio Seeks $8 Million in Public Offering Amid Nasdaq Compliance Concerns

GRI Bio launches a public offering of common stock and warrants to raise up to $8 million as it faces Nasdaq listing deficiencies and aims to fund clinical trials.

Summary

• GRI Bio, Inc. is offering up to 3,871,467 shares of common stock along with Series B-1 and B-2 common warrants.
• The offering also includes pre-funded warrants as an alternative for purchasers who would exceed beneficial ownership limits.
• The combined public offering price is assumed to be $2.066 per share and accompanying warrants, based on the closing price on January 29, 2024.
• The warrants have an exercise price of $2.066 per share and are exercisable immediately upon issuance.
• Series B-1 warrants expire five years from issuance, while Series B-2 warrants expire after 18 months.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• GRI Bio is facing Nasdaq compliance issues related to minimum stockholders' equity and bid price requirements.
• The company received an extension until May 20, 2024, to regain compliance with the stockholders' equity requirement, needing to raise at least $6 million in gross proceeds.
• A reverse stock split was implemented in January 2024 to address the bid price deficiency.
• The offering may be terminated if all securities are sold or with five business days' notice.
• A.G.P./Alliance Global Partners is acting as the placement agent for the offering.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is developing promising therapies and has received FDA clearance for its IND application for GRI-0621, it is also facing significant financial challenges and Nasdaq compliance issues. The auditor's going concern warning further dampens the sentiment.

Positives

• The offering provides an opportunity to raise capital for working capital and general corporate purposes.
• The company has a Phase 2a biomarker study for GRI-0621 underway, with topline results expected in the second half of 2024.
• The company has a proprietary library of 500+ compounds and is developing GRI-0803 for autoimmune disorders.
• The company has received FDA clearance for its IND application for GRI-0621 for the treatment of IPF.

Negatives

• The company has incurred significant net losses since inception and expects to continue to do so.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is facing Nasdaq compliance issues related to minimum stockholders' equity and bid price requirements.
• The offering is on a reasonable best efforts basis with no minimum amount required to be sold.
• There is no established public trading market for the pre-funded warrants or the common warrants.

Risks

• The company may not raise the amount of capital it believes is required to continue its operations and to regain compliance with the Stockholders Equity Requirement.
• Holders of the Pre-Funded Warrants or the Common Warrants purchased in this offering will have no rights as common stockholders until such holders exercise their Pre-Funded Warrants or Common Warrants and acquire our Common Stock.
• The company will require substantial additional capital in addition to any proceeds from this offering to finance its operations and to potentially maintain or regain compliance with the Stockholders Equity Requirement.
• The company's business is highly dependent on the success of its lead product candidate, GRI-0621, and any other product candidates that it may advance into clinical development.
• The company relies on third parties to conduct its clinical trials, manufacture its product candidates and perform other services.
• The company expects the stock price of its Common Stock to be highly volatile.
• Future sales and issuances of the company's securities could result in additional dilution of the percentage ownership of its stockholders and could cause its share price to fall.
• A delisting of the company's Common Stock from Nasdaq could subject it to substantial financial penalties and/or adversely affect its ability to raise additional capital through the public or private sale of equity securities and its investors ability to dispose of, or obtain accurate quotations as to the market value of, its Common Stock.
• The January 2024 Reverse Stock Split could cause the company's stock price to decline relative to its value before the split and decrease the liquidity of shares of its Common Stock.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future and will require additional funding to support its planned operating activities. Topline data from the Phase 2a trial is expected in the second half of 2024.

Industry Context

The biopharmaceutical industry is highly competitive, with many companies developing products for the same indications. GRI Bio faces competition from larger companies with greater resources and established market presence.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, it mentions that current IPF therapies, such as nintedanib (OFEV) and pirfenidone (Esbriet), have limitations, including significant side effects and no improvements in overall survival.
• GRI Bio aims to develop GRI-0621 as a disease-modifying therapy for IPF, which could potentially offer advantages over existing treatments.
• The document also notes that only two drugs have been approved for lupus in the past 50 years, indicating a significant unmet need in this therapeutic area.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• Employees may be affected by potential reductions in spending or scaling back of development programs if the company is unable to raise sufficient capital.
• Patients with IPF and autoimmune disorders may benefit from the development of new therapies.
• Suppliers and creditors may be affected by potential delays in payment or changes in operating plans if the company faces financial difficulties.

Next Steps

• Complete the public offering to raise capital.
• Continue the Phase 2a trial for GRI-0621 in IPF and report topline results in the second half of 2024.
• File an IND for GRI-0803 and evaluate it in a Phase 1a and 1b trial initially targeting SLE.
• Evaluate strategic collaborations and partnerships to expand the product portfolio.

Key Dates

Keywords

GRI Bio, public offering, common stock, warrants, pre-funded warrants, Nasdaq compliance, clinical trials, GRI-0621, GRI-0803, biopharmaceutical